ReviewNature reviews. Disease primers2025
Thoracic aortic aneurysm.
Review in Nature reviews. Disease primers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- Current options and recommendations for the treatment of aortic arch diseases.Annals of cardiothoracic surgery · 2026Article
- Fibronectin-induced overactivation of αNature communications · 2026Article
- Piceatannol attenuates thoracic aortic aneurysm progression by targeting STK33.Biology direct · 2026Article
- Pathogenesis, Diagnosis, and Clinical Management of Aortic Aneurysms: Current Status and Future Perspectives.Reviews in cardiovascular medicine · 2026Review
- An Overview of the Diagnostic and Treatment Strategies for Aortic Disease.Reviews in cardiovascular medicine · 2026Review
- Ultrasound-guided left heart injection: a safer and more efficient strategy for mouse thoracic aortic gene delivery.Gene therapy · 2026Article
- Global, regional, and national burden of aortic aneurysm and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.International journal of surgery (London, England) · 2026Article
- Mechanistic Insight into PVAT Browning as a Protective Factor in Thoracic Aortic Aneurysm.Current atherosclerosis reports · 2026Review
- Pro-resolving lipid mediators in diseases: exploring the molecular basis and clinical implication.Molecular biomedicine · 2026Review
- Aging, matrix metalloproteinase imaging, and survival prospects in aortic aneurysm.bioRxiv : the preprint server for biology · 2026Article
- Editorial: Molecular advances and new insights in aortic aneurysmal diseases.Frontiers in cell and developmental biology · 2026Article
- Review
- Thoracic aortic aneurysm combined with intracranial vascular abnormalities caused by dual mutations inFrontiers in genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aortic medicine has undergone remarkable progress in recent decades with regard to our understanding and treatment of aortic disease. In the past decade, the scientific community has called for the aorta to be viewed as an independent organ, advocating for a holistic approach to understanding thoracic aortic disease, integrating its embryological development, wall composition, pathophysiological mechanisms, surveillance and treatment. Thoracic aortic aneurysm (TAA) is a potentially fatal disease characterized by abnormal dilation of the thoracic aorta, whereby the structural integrity of the vessel wall is compromised. Although epidemiological studies of TAA are confounded by its asymptomatic nature and diagnostic challenges, available evidence suggests that TAA prevalence and treatment outcomes vary according to race, sex and socioeconomic factors. Pathophysiological mechanisms involve interactions between vascular smooth muscle cells and the extracellular matrix, influenced by genetic predisposition and embryological factors as well as arterial hypertension. Diagnosis relies on advanced imaging techniques, with CT angiography considered to be the gold standard diagnostic tool and with genetic screening recommended for heritable conditions. Preventive measures focus on managing cardiovascular risk factors, whereas treatment includes medical management, as well as endovascular and open surgical repair. TAA has a major effect on quality of life, particularly in younger, female and genetically predisposed patients, necessitating further research and tailored interventions.
Indexed as
Identifiers
40341396What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.